Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioray Biotech CoROCO:7561 +2.45%86 Debt-to-EBITDA is 1.87 as of Jun. 2026, which is 40% below its 10-year median of 3.10. GuruFocus rates ROCO:7561 with a GF Score™ of 86/100 and a GF Value™ of NT$24.37 (Fairly Valued). The stock has 1 warning sign investors should review. Among 675 Drug Manufacturers companies, Bioray Biotech Co ranks better than 52.3% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bioray Biotech Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:7561'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.5 Med: 3.1 Max: 5.75
Current: 1.48
During the past 9 years, the highest Debt-to-EBITDA Ratio of Bioray Biotech Co was 5.75. The lowest was 0.50. And the median was 3.10.
ROCO:7561's Debt-to-EBITDA is ranked better than 52.3% of 675
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs ROCO:7561: 1.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bioray Biotech Co Debt-to-EBITDA Related Terms
Bioray Biotech Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bioray Biotech Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Bioray Biotech Co (ROCO:7561) has a Debt-to-EBITDA of 1.87 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bioray Biotech Co. This is 40% below median its historical median of 3.10. Over the past decade, Bioray Biotech Co's Debt-to-EBITDA has ranged from 0.50 to 5.75. According to the industry distribution chart, Bioray Biotech Co ranks #322 out of 675 companies in the Drug Manufacturers industry, placing it in the top 47.7%.
Is Bioray Biotech Co's Debt-to-EBITDA too high?
Bioray Biotech Co's current Debt-to-EBITDA of 1.87 is 40% below median its 10-year median of 3.10. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 5.75. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Bioray Biotech Co's value of 1.87 is 14% above this industry median. Based on the distribution chart, Bioray Biotech Co ranks #322 out of 675 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bioray Biotech Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #322 out of 675 companies for Debt-to-EBITDA. This puts Bioray Biotech Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Bioray Biotech Co's value of 1.87 is 14% above this benchmark. Historically, Bioray Biotech Co's own Debt-to-EBITDA has ranged from 0.50 to 5.75 over the past decade. While the company's 10-year median is 3.10 vs. the industry median of 1.64, Bioray Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 675 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current Debt-to-EBITDA of 1.87 is 14% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bioray Biotech Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current Debt-to-EBITDA is 1.87, which is 40% below median its own 10-year median of 3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Fairly Valued. The stock's GF Value™ is NT$24.37, compared to a current price of NT$23.00 — trading 5.6% below its estimated fair value. The current Debt-to-EBITDA is 1.87, which is 40% below median its 10-year median of 3.10 and 14% above the Drug Manufacturers industry median of 1.64. Bioray Biotech Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current Debt-to-EBITDA is 1.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$23.00 is trading 5.6% below its estimated GF Value™ of NT$24.37.
GuruFocus considers Bioray Biotech Co to be Fairly Valued.
Key valuation signals for ROCO:7561:
Debt-to-EBITDA: 1.87 (40% below median its 10-year median of 3.10)
GF Value™: NT$24.37 vs. price of NT$23.00 (5.6% below fair value)
Industry Position: 14% above the Drug Manufacturers median (#322 of 675)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
86GF Score
Get the complete analysis for ROCO:7561
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
